The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan
The journey to implement cancer genomic medicine (CGM) in oncology practice began in the 1980s, which is considered the dawn of genetic and genomic cancer research. At the time, a variety of activating oncogenic alterations and their functional significance were unveiled in cancer cells, which led t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2024-01-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/21/1/29 |
| _version_ | 1797306775940104192 |
|---|---|
| author | Teruhiko Yoshida Yasushi Yatabe Ken Kato Genichiro Ishii Akinobu Hamada Hiroyuki Mano Kuniko Sunami Noboru Yamamoto Takashi Kohno |
| author_facet | Teruhiko Yoshida Yasushi Yatabe Ken Kato Genichiro Ishii Akinobu Hamada Hiroyuki Mano Kuniko Sunami Noboru Yamamoto Takashi Kohno |
| author_sort | Teruhiko Yoshida |
| collection | DOAJ |
| description | The journey to implement cancer genomic medicine (CGM) in oncology practice began in the 1980s, which is considered the dawn of genetic and genomic cancer research. At the time, a variety of activating oncogenic alterations and their functional significance were unveiled in cancer cells, which led to the development of molecular targeted therapies in the 2000s and beyond. Although CGM is still a relatively new discipline and it is difficult to predict to what extent CGM will benefit the diverse pool of cancer patients, the National Cancer Center (NCC) of Japan has already contributed considerably to CGM advancement for the conquest of cancer. Looking back at these past achievements of the NCC, we predict that the future of CGM will involve the following: 1) A biobank of paired cancerous and non-cancerous tissues and cells from various cancer types and stages will be developed. The quantity and quality of these samples will be compatible with omics analyses. All biobank samples will be linked to longitudinal clinical information. 2) New technologies, such as whole-genome sequencing and artificial intelligence, will be introduced and new bioresources for functional and pharmacologic analyses (e.g., a patient-derived xenograft library) will be systematically deployed. 3) Fast and bidirectional translational research (bench-to-bedside and bedside-to-bench) performed by basic researchers and clinical investigators, preferably working alongside each other at the same institution, will be implemented; 4) Close collaborations between academia, industry, regulatory bodies, and funding agencies will be established. 5) There will be an investment in the other branch of CGM, personalized preventive medicine, based on the individual’s genetic predisposition to cancer. |
| first_indexed | 2024-03-08T00:46:42Z |
| format | Article |
| id | doaj.art-098513c931e64fbb831a95e5cc3e139e |
| institution | Directory Open Access Journal |
| issn | 2095-3941 |
| language | English |
| last_indexed | 2024-03-08T00:46:42Z |
| publishDate | 2024-01-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-098513c931e64fbb831a95e5cc3e139e2024-02-15T06:04:29ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412024-01-01211294410.20892/j.issn.2095-3941.2023.0036The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center JapanTeruhiko Yoshida0Yasushi Yatabe1Ken Kato2Genichiro Ishii3Akinobu Hamada4Hiroyuki Mano5Kuniko Sunami6Noboru Yamamoto7Takashi Kohno8Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo 104-0045, JapanDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, JapanClinical Research Support Office, Clinical Research Coordinating Section, Biobank Translational Research Support Section, National Cancer Center Hospital, Tokyo 104-0045, JapanDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba 277-8577, JapanDivision of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo 104-0045, JapanNational Cancer Center Research Institute, Tokyo 104-0045, JapanDepartment of Laboratory Medicine, National Cancer Center Hospital, Tokyo 104-0045, JapanDepartment of Experimental Therapeutics, National Cancer Center Hospital, Tokyo 104-0045, JapanDivision of Genome Biology, National Cancer Center Research Institute, Tokyo 104-0045, JapanThe journey to implement cancer genomic medicine (CGM) in oncology practice began in the 1980s, which is considered the dawn of genetic and genomic cancer research. At the time, a variety of activating oncogenic alterations and their functional significance were unveiled in cancer cells, which led to the development of molecular targeted therapies in the 2000s and beyond. Although CGM is still a relatively new discipline and it is difficult to predict to what extent CGM will benefit the diverse pool of cancer patients, the National Cancer Center (NCC) of Japan has already contributed considerably to CGM advancement for the conquest of cancer. Looking back at these past achievements of the NCC, we predict that the future of CGM will involve the following: 1) A biobank of paired cancerous and non-cancerous tissues and cells from various cancer types and stages will be developed. The quantity and quality of these samples will be compatible with omics analyses. All biobank samples will be linked to longitudinal clinical information. 2) New technologies, such as whole-genome sequencing and artificial intelligence, will be introduced and new bioresources for functional and pharmacologic analyses (e.g., a patient-derived xenograft library) will be systematically deployed. 3) Fast and bidirectional translational research (bench-to-bedside and bedside-to-bench) performed by basic researchers and clinical investigators, preferably working alongside each other at the same institution, will be implemented; 4) Close collaborations between academia, industry, regulatory bodies, and funding agencies will be established. 5) There will be an investment in the other branch of CGM, personalized preventive medicine, based on the individual’s genetic predisposition to cancer.https://www.cancerbiomed.org/content/21/1/29cancer genomic medicinebiobankpatient-derived xenograftmulti-gene panel testwhole genome sequencing |
| spellingShingle | Teruhiko Yoshida Yasushi Yatabe Ken Kato Genichiro Ishii Akinobu Hamada Hiroyuki Mano Kuniko Sunami Noboru Yamamoto Takashi Kohno The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan Cancer Biology & Medicine cancer genomic medicine biobank patient-derived xenograft multi-gene panel test whole genome sequencing |
| title | The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan |
| title_full | The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan |
| title_fullStr | The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan |
| title_full_unstemmed | The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan |
| title_short | The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan |
| title_sort | evolution of cancer genomic medicine in japan and the role of the national cancer center japan |
| topic | cancer genomic medicine biobank patient-derived xenograft multi-gene panel test whole genome sequencing |
| url | https://www.cancerbiomed.org/content/21/1/29 |
| work_keys_str_mv | AT teruhikoyoshida theevolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT yasushiyatabe theevolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT kenkato theevolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT genichiroishii theevolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT akinobuhamada theevolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT hiroyukimano theevolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT kunikosunami theevolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT noboruyamamoto theevolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT takashikohno theevolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT teruhikoyoshida evolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT yasushiyatabe evolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT kenkato evolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT genichiroishii evolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT akinobuhamada evolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT hiroyukimano evolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT kunikosunami evolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT noboruyamamoto evolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan AT takashikohno evolutionofcancergenomicmedicineinjapanandtheroleofthenationalcancercenterjapan |